CureVac NV - Asset Resilience Ratio

Latest as of September 2025: 0.27%

CureVac NV (5CV) has an Asset Resilience Ratio of 0.27% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check 5CV strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets

€3.12 Million

≈ $3.65 Million USD Cash + Short-term Investments

Total Assets

€1.14 Billion

≈ $1.33 Billion USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2018–2024)

This chart shows how CureVac NV's Asset Resilience Ratio has changed over time. See 5CV net asset quality score to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down CureVac NV's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 5CV market cap overview.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€0.00	0%
Short-term Investments	€3.12 Million	0.27%
Total Liquid Assets	€3.12 Million	0.27%

Asset Resilience Insights

Limited Liquidity: CureVac NV maintains only 0.27% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

CureVac NV Industry Peers by Asset Resilience Ratio

Compare CureVac NV's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Ascendis Pharma AS NASDAQ:ASND	Biotechnology	0.00%
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	0.00%
Spyre Therapeutics Inc. NASDAQ:SYRE	Biotechnology	84.34%
3SBio Inc F:83B	Biotechnology	10.64%
Soleno Therapeutics Inc NASDAQ:SLNO	Biotechnology	20.15%
Jiangxi Fushine Pharmaceutical Co Ltd SHE:300497	Biotechnology	0.02%
Novavax Inc NASDAQ:NVAX	Biotechnology	53.87%
BB Biotech AG SW:BION	Biotechnology	0.05%

Annual Asset Resilience Ratio for CureVac NV (2018–2024)

The table below shows the annual Asset Resilience Ratio data for CureVac NV.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	0.45%	€3.62 Million ≈ $4.23 Million	€802.83 Million ≈ $938.59 Million	+0.11pp
2023-12-31	0.34%	€2.66 Million ≈ $3.11 Million	€788.25 Million ≈ $921.55 Million	-0.18pp
2022-12-31	0.52%	€4.49 Million ≈ $5.25 Million	€860.47 Million ≈ $1.01 Billion	+0.12pp
2021-12-31	0.40%	€4.65 Million ≈ $5.43 Million	€1.16 Billion ≈ $1.35 Billion	+0.23pp
2020-12-31	0.17%	€2.62 Million ≈ $3.06 Million	€1.51 Billion ≈ $1.77 Billion	-0.94pp
2019-12-31	1.12%	€1.46 Million ≈ $1.70 Million	€130.62 Million ≈ $152.71 Million	-30.12pp
2018-12-31	31.24%	€39.25 Million ≈ $45.89 Million	€125.66 Million ≈ $146.91 Million	--

pp = percentage points

About CureVac NV

F:5CV Germany Biotechnology

Market Cap

$1.03 Billion

€879.52 Million EUR

Market Cap Rank

#9612 Global

#1178 in Germany

Share Price

€3.91

Change (1 day)

-0.61%

52-Week Range

€3.42 - €4.75

All Time High

€108.20